



SCHERING-POLOUGH CORPORATION AT A GLANCE

Chairman and CEO : Fred Hassan

Global Headquarters : Kenilworth, N.J., U.S.A.

Total Number of Employees : 33,500

2006 Net Sales : \$10.6 billion

2006 R&D Investment : \$2.2 billion

R&D Centers : New Jersey, Massachusetts, California and Italy

Major prescription products:

- ZETIA¹, a novel cholesterol-absorption inhibitor
- VYTORIN¹, a cholesterol-lowering medicine containing ZETIA and Merck & Co., Inc.'s statin *Zocor*
- REMICADE² for rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis and psoriasis
- NASONEX, a nasal-inhaled steroid for nasal allergy symptoms
- PEG-INTRON, A pegylated interferon for chronic hepatitis C; PEG-INTRON REDIPEN injection pen
- The CLARINEX family of nonsedating antihistamines (some in combination with decongestant)
- TEMODAR Capsules for certain types of brain tumors

1 – Sold through the Merck/Schering-Plough Joint Venture

2 – Sold by Schering-Plough outside the U.S. only

Major consumer healthcare products:

- CLARITIN, nonsedating antihistamines
- CORICIDIN, cough/cold tablets
- DR. SCHOLL'S, foot care products
- COPPERTONE, sun care products

Major animal health products:

- OTOMAX, canine otic ointment
- NUFLOR, antibiotic for cattle, swine and fish
- BANAMINE, anti-inflammatory for cattle, horses and swine

Global Animal Management: Subsidiary provides animal data management services to the livestock industry.

Schering-Plough People Around the World:

Worldwide Total	: 33,500
U.S.	: 14,000
Other Countries	: 19,000
New Jersey	: 7,700
Schering-Plough Research Institute	: 3,900
Schering-Plough Animal Health	: 1,300 (excludes all other functions that support Animal Health)